BEIJING (Reuters) – China’s National Medical Products Administration has granted green lights for Novo Nordisk’s insulin icodec injection used for the treatment of Type-2 diabetes among adults to enter the Chinese market, it said on Monday.
(Reporting by Ella Cao and Ryan Woo, Editing by Louise Heavens)
Comments